2395 — Shin Nippon Biomedical Laboratories Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.68 | ||
| PEG Ratio (f) | 10.57 | ||
| EPS Growth (f) | 1.41% | ||
| Dividend Yield (f) | 3.4% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.47 | ||
| Price to Tang. Book | 1.55 | ||
| Price to Free Cashflow | 20.49 | ||
| Price to Sales | 1.81 | ||
| EV to EBITDA | 11.26 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.72% | ||
| Return on Equity | 13.9% | ||
| Operating Margin | 12.03% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 17,748.48 | 25,090.9 | 26,450.47 | 32,413.81 | 32,524.96 | 38,483 | 41,691 | 16.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +90.27 | +17.45 | -21.8 | -4.36 | -19.06 | -10.64 | +11.7 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shin Nippon Biomedical Laboratories Ltd is a Japan-based company mainly engaged in contract research organization (CRO) business, translational research business, and other businesses. It operates through four segments. CRO segment uses experimental animals, cells, and bacteria to confirm efficacy and safety. The Translational Research segment develops intranasal formulations, discovers seed technologies and new substances, conducts non-clinical and clinical trials necessary for the evaluation and approval of pharmaceuticals, and commercializes these products by demonstrating basic theories in clinical settings to increase added value. The Medipolis segment operates accommodation facilities and geothermal power generation businesses. The U.S. Real Estate segment leases multi-purpose industrial buildings constructed on land owned by its U.S. subsidiary. The Company is also engaged in construction, administrative outsourcing, cleaning, and on-site convenience store operations.
Directors
- Ryoichi Nagata CHM (63)
- Shinji Nitanda CFO (53)
- Fumihiko Makino FID
- Ken Takanashi COO (57)
- Shuichi Kanazashi CMO (61)
- Hideshi Tsusaki SMD (54)
- Ichiro Nagata MDR (36)
- Takashi Iriyama MEO
- Satoshi Matsumoto MEO (53)
- Kyomi Nagatoshi SEO
- Terumasa Hirai SEO
- Toshiyuki Iwata SEO
- Shunji Haruta EXO
- Tomoaki Honda EXO
- Takahiro Nakamura EXO
- Takatoshi Nakamura EXO
- Guodong Zheng EXO
- Shinichi Fukumoto IND (63)
- Tsuyoshi Hanada IND (63)
- Keiko Totani IND (57)
- Takashi Yamashita IND (65)
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- May 18th, 1973
- Public Since
- March 8th, 2004
- No. of Shareholders
- 13,112
- No. of Employees
- 1,522
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 41,631,814
- Address
- 28F, St Luke's Tower, 8-1, Akashi-cho, CHUO-KU, 104-0044
- Web
- https://snbl.com
- Phone
- +81 355655001
- Auditors
- KPMG AZSA LLC
Latest News for 2395
Upcoming Events for 2395
Q2 2027 Shin Nippon Biomedical Laboratories Ltd Earnings Release
Dividend For 2395.T - 30.0000 JPY
Similar to 2395
3-D Matrix
Tokyo Stock Exchange
ADR Biomedical Holdings
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
FAQ
As of Today at 05:16 UTC, shares in Shin Nippon Biomedical Laboratories are trading at ¥1,472. This share price information is delayed by 15 minutes.
Shares in Shin Nippon Biomedical Laboratories last closed at ¥1,472 and the price had moved by -5.28% over the past 365 days. In terms of relative price strength the Shin Nippon Biomedical Laboratories share price has underperformed the Nikkei 225 Index by -26.51% over the past year.
The overall consensus recommendation for Shin Nippon Biomedical Laboratories is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Shin Nippon Biomedical Laboratories dividend yield is 3.4% based on the trailing twelve month period.
Last year, Shin Nippon Biomedical Laboratories paid a total dividend of ¥50, and it currently has a trailing dividend yield of 3.4%.Looking ahead, the next dividend pay date is 2026-11-30.
We do not have data on when Shin Nippon Biomedical Laboratories is to next pay dividends. The historic dividend yield on Shin Nippon Biomedical Laboratories shares is currently 3.4%.
To buy shares in Shin Nippon Biomedical Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥1,472, shares in Shin Nippon Biomedical Laboratories had a market capitalisation of ¥61bn.
Here are the trading details for Shin Nippon Biomedical Laboratories:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 2395
Based on an overall assessment of its quality, value and momentum Shin Nippon Biomedical Laboratories is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Shin Nippon Biomedical Laboratories is ¥1,693. That is 15.05% above the last closing price of ¥1,472.
Analysts covering Shin Nippon Biomedical Laboratories currently have a consensus Earnings Per Share (EPS) forecast of ¥94 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shin Nippon Biomedical Laboratories. Over the past six months, its share price has underperformed the Nikkei 225 Index by -1.09%.
As of the last closing price of ¥1,472, shares in Shin Nippon Biomedical Laboratories were trading +4.31% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shin Nippon Biomedical Laboratories PE ratio based on its reported earnings over the past 12 months is 14.68. The shares last closed at ¥1,472.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shin Nippon Biomedical Laboratories' management team is headed by:
- Ryoichi Nagata - CHM
- Shinji Nitanda - CFO
- Fumihiko Makino - FID
- Ken Takanashi - COO
- Shuichi Kanazashi - CMO
- Hideshi Tsusaki - SMD
- Ichiro Nagata - MDR
- Takashi Iriyama - MEO
- Satoshi Matsumoto - MEO
- Kyomi Nagatoshi - SEO
- Terumasa Hirai - SEO
- Toshiyuki Iwata - SEO
- Shunji Haruta - EXO
- Tomoaki Honda - EXO
- Takahiro Nakamura - EXO
- Takatoshi Nakamura - EXO
- Guodong Zheng - EXO
- Shinichi Fukumoto - IND
- Tsuyoshi Hanada - IND
- Keiko Totani - IND
- Takashi Yamashita - IND